Cyclomics BV, a pioneer in liquid biopsy technology, announces the successful closing of a new investment round led by Myosotis Investments and supported by Oncode Bridge Fund. This capital infusion marks a pivotal transition for the company as it expands its commercial operations to bring innovative diagnostic products to cancer patients.
Cyclomics secures new investment to accelerate commercialization of ultra-sensitive cancer diagnostics by fast and high-resolution DNA sequencing strategies. This new investment round is led by Myosotis Investments and with continued support from Oncode Bridge Fund. The funding will help accelerate the translation of innovative cancer diagnostics from research into clinical practice: with clear benefits for patients.
The company is developing diagnostic technologies that enable doctors to detect cancer earlier and more accurately, using minimally invasive methods such as blood-based testing. Cyclomics’ lead technology, CyclomicsSeq™, can detect very small traces of cancer DNA in the bloodstream, making it possible to diagnose cancer earlier and monitor disease progression with greater precision. For patients, this could mean fewer invasive procedures, faster diagnosis, and more personalized treatment. The technology has already been validated in collaboration with leading medical centers.
Cyclomics’ lead technology, CyclomicsSeq™, can detect very small traces of cancer DNA in the bloodstream, making it possible to diagnose cancer earlier and monitor disease progression with greater precision. For patients, this could mean fewer invasive procedures, faster diagnosis, and more personalized treatment. The technology has already been validated in collaboration with leading medical centers.
With this new investment, Cyclomics will expand its team, prepare its diagnostic products for use in hospitals, and further develop Epinn™, a software platform that supports faster and more accurate cancer classification.
Shobhit Dhawan, PhD, Managing Director of Oncode Bridge Fund
"From the outset, we supported Cyclomics, drawn by the rigor of its science and the strength of its entrepreneurial team. The development of the CyclomicsSeq™ and Epinn™ platforms, together with the collaboration with Oxford Nanopore Technologies, demonstrates the company’s strong translational potential and focus on delivering meaningful solutions for cancer patients. This latest financing marks a key step in expanding Cyclomics’ impact in oncology."
Wigard Kloosterman, Founder and CEO of Cyclomics BV.
"With the support of Myosotis Investments and Oncode Bridge Fund, we will accelerate our product development and build a team capable of driving sales to make global impact in cancer diagnostics,"
Prof. dr. ir. Jeroen de Ridder, co-founder of Cyclomics, Oncode Investigator and Professor in Bioinformatics in Molecular Medicine at the UMC Utrecht and University Utrecht.
“Early intervention relies on rapid and superior diagnostic capability. We have validated our technology in clinical environments, achieving rapid diagnosis from tumor biopsies and exceptional sensitivity through non-invasive blood analysis. This is a crucial step forward for improving patient outcomes.”
Wietse Mulder, PhD, Managing Director of Myosotis BV.
"I have observed Cyclomics evolving into a powerhouse of innovation. I am happy to support them with my expertise in commercialization, such to transform Cyclomics and her multidisciplinary team into an independent provider of innovative diagnostic tools, ultimately enhancing better care of patients suffering from cancer."
The Oncode Oncology Bridge Fund helps bring innovative cancer research from the lab to real-world impact. This fund supports the creation and growth of spin-off companies founded on discoveries by Oncode Institute researchers, speeding up new treatments for patients and benefits for society.